Abstract: FR-PO0872
Driver of Cardiovascular Mortality in ANCA-Associated Vasculitis
Session Information
- Glomerular Outcomes: From Proteinuria to Prognosis
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Tangwanchai, Taksaporn, The University of Manchester Faculty of Biology Medicine and Health, Manchester, England, United Kingdom
- Kashif, Kinza, The University of Manchester Faculty of Biology Medicine and Health, Manchester, England, United Kingdom
- Barrett, Emma, Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
- Brix, Silke R., Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
Background
Cardiovascular mortality is significantly higher in patients with antineutrophil cytoplasmic antibody (ANCA) vasculitis compared to the general population assuming chronic inflammation drives escalated atherosclerosis. We reviewed the prevalence and specifics of cardiovascular disease in our single centre ANCA vasculitis cohort investigating classical and vasculitis related risk parameters such as gender, smoking, antihypertension treatment, kidney function and organ failure.
Methods
A total of 288 patients (2006 – 2025) were retrospectively reviewed who fullfilled the Chapel Hill Criteria for ANCA vasculitis.
Results
Of all patients, 34.03% had a recorded cardiovascular disease (CVD) event with 16.32% before and 17.71% following the diagnosis of ANCA vasculitis, significantly higher than the current estimate in the general UK population. Patients were fewer Never smokers (51.04%) compared to the general population; 40.28% recorded as Ex-smokers and a remaining 6.25% as Active smokers.
Active and Ex smokers demonstrated higher numbers of CVD in their past medical history prior to the onset of ANCA vasculitis compared to Never smokers (27.8%, 18.1% vs 13.6%). Following the diagnosis of vasculitis, CVD events did not differ between Never and Ex smokers (19.1% and 18.1%) but were more frequent then in the general population. Of the total cohort, 10 patients (3.5%) suffered a myocardial infarction, 10 (3.5%) underwent percutaneous intervention and 8 (2.8%) a coronary bypass graft, 19 patients (6.6%) suffered a cerebo-vascular accident and 6 (2.1%) from peripheral vascular disease.
70.2% of patients received antihypertensive medication and 29.8% of patients did not. 15.3% of patients received sodium-glucose co-transporter 2 inhibitor treatment for proteinuric chronic kidney disease.
Conclusion
Smoking seems to worsen CVD related outcomes as previously suggested. Smoking cessation is therefore a priority, and structured programs and pharmacological aids are important to reduce the additional risk factor smoking.
Funding
- Government Support – Non-U.S.